Bluebird Hit With Slow Uptake of Sickle Cell, Beta-Thalassemia Gene Therapies

Likely to miss its initiation target, bluebird bio has renegotiated the loan deals of its agreement with Hercules Capital, giving it until June 30 next year—at the latest.

Read more about this post on Biospace